SEC Form 4 · accession 0000891293-19-000010
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirske
Officer — EVP, Chief Financial Officer
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 6:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $0.9489 | Feb 19, 2019 | A | 500,000 | A | — | Feb 19, 2029 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F11/3 of the shares subject to the Option shall vest on the one year anniversary of February 19, 2019, and 1/3 of the shares shall vest annually thereafter on February 19, subject to Reporting Person continuing to be an employee or service provider on each date, such that the Option shall be fully vested on February 19, 2022.